"Most pathologists look at thick sections of RSV in formaldehyde, but our 3D structures are more fluid and amorphous than the solid structures pathologists have observed," Santangelo said. "The more we know about how RSV really looks, the more we'll understand about its pathogenesis."
RSV is the most important cause of respiratory infection in young children worldwide, infecting virtually every child in the first few years of life. Immunity is feeble and fleeting, and repeated infections are the rule. One in every 100 or 200 infected infants requires hospitalization, usually for bronchiolitis. There is not yet an effective vaccine for RSV, and current anti-viral drugs are in their infancy in terms of efficacy, Santangelo noted.
Ultimately, researchers want to conduct in vivo testing, but must first adapt their molecular beacons technology for that purpose, Santangelo said. "In the nearer term, we hope to use molecular beacons to detect RSV in clinical samples like with those taken with a nasal swab. We might be able to detect RSV in its first day of incubation and make an early diagnosis,'' he added.
The researchers also hope their research will lead to development of a suite of anti-viral drugs for treating RSV and other viruses, including human influenza.
Page: 1 2 3 Related medicine news :1
Contact: Jane Sanders
Georgia Institute of Technology Research News
. Elsevier launches Molecular Oncology2
. Molecular marker may help identify pancreatic cancer, and possibly predict survival time3
. Molecular differences between early and advanced melanomas could provide new drug targets4
. Molecular structure reveals how botulinum toxin attaches to nerve cells5
. Molecular medicine comes to the rescue6
. Molecular switch may turn off immune cells that target HIV7
. The Molecular Profiling Institute, Inc. and IBM advance technology8
. Molecular Profiling Institute secures $7.5 million in Series B funding9
. Molecular studies in cancer of the colon10
. Molecular ballet unravels, links proteins so cell can direct own movement11
. Molecular testing in patients with rare cancer predicts response to Gleevec